|
End-of-day quote
Prague S.E.
2026-09-11
|
5-day change | 1st Jan Change | ||
| 114.00 CZK | -1.72% |
|
-2.56% | -32.94% |
| 06-14 | Pilulka Lékárny a.s. Auditor Raises 'Going Concern' Doubt | CI |
| 06-14 | Pilulka Lékárny a.s. Reports Earnings Results for the Full Year Ended December 31, 2025 | CI |
| Fiscal Period: December | 2021 (CZK) | 2022 (CZK) | 2023 (CZK) | 2024 (CZK) | 2025 (CZK) |
|---|---|---|---|---|---|
Profitability | |||||
Return on Assets | - | -4.99 | -17.76 | -20.29 | -4.74 |
Return on Total Capital | - | -17.4 | -56.04 | -231.28 | 15.74 |
Return On Equity % | - | -38.34 | -207.35 | 382.73 | 32.92 |
Return on Common Equity | - | -37.7 | -202.26 | 411.4 | 34.12 |
Margin Analysis | |||||
Gross Profit Margin % | 0.57 | 0.01 | 13.95 | 14.07 | 14.9 |
SG&A Margin | - | - | 17.1 | 17.57 | 20.62 |
EBITDA Margin % | 0.35 | -1.22 | -5.9 | -6.92 | -0.17 |
EBITA Margin % | -0.04 | -1.82 | -6.85 | -8.25 | -1.61 |
EBIT Margin % | -0.59 | -1.95 | -6.97 | -8.43 | -1.88 |
Income From Continuing Operations Margin % | -1.08 | -2.69 | -8.25 | -9.69 | -4.41 |
Net Income Margin % | -1.07 | -2.65 | -8.21 | -9.64 | -4.43 |
Net Avail. For Common Margin % | -1.07 | -2.65 | -8.21 | -9.64 | -4.43 |
Normalized Net Income Margin | -0.64 | -1.6 | -5.11 | -6.42 | -2.9 |
Levered Free Cash Flow Margin | - | -0.92 | 0.29 | 4.7 | 2.13 |
Unlevered Free Cash Flow Margin | - | -0.8 | 0.6 | 5.29 | 3.34 |
Asset Turnover | |||||
Asset Turnover | - | 4.1 | 4.08 | 3.85 | 4.03 |
Fixed Assets Turnover | - | 35.78 | 32.31 | 33.12 | 58.15 |
Receivables Turnover (Average Receivables) | - | 16.39 | 15.98 | 13.21 | 16.42 |
Inventory Turnover (Average Inventory) | - | 14.29 | 12.95 | 14.85 | 12.63 |
Short Term Liquidity | |||||
Current Ratio | 1.13 | 0.92 | 0.71 | 0.45 | 0.44 |
Quick Ratio | 0.7 | 0.49 | 0.45 | 0.27 | 0.24 |
Operating Cash Flow to Current Liabilities | 0.07 | -0.09 | -0.09 | -0.14 | -0.06 |
Days Sales Outstanding (Average Receivables) | - | 22.27 | 22.83 | 27.71 | 22.24 |
Days Outstanding Inventory (Average Inventory) | - | 25.54 | 28.19 | 24.64 | 28.9 |
Average Days Payable Outstanding | - | - | 64.79 | 74.79 | 75.19 |
Cash Conversion Cycle (Average Days) | - | - | -13.77 | -22.44 | -24.05 |
Long Term Solvency | |||||
Total Debt/Equity | - | - | 250.77 | -50.08 | -40.1 |
Total Debt / Total Capital | - | - | 71.49 | -100.31 | -66.95 |
LT Debt/Equity | - | - | 11.97 | -2.48 | -0.87 |
Long-Term Debt / Total Capital | - | - | 3.41 | -4.97 | -1.45 |
Total Liabilities / Total Assets | 65.36 | 77.07 | 93.02 | 140.76 | 169.95 |
EBIT / Interest Expense | -18.08 | -10.02 | -14.18 | -8.91 | -0.97 |
EBITDA / Interest Expense | 10.63 | -6.27 | -12 | -7.32 | -0.09 |
(EBITDA - Capex) / Interest Expense | -95.07 | -22.39 | -15.4 | -8.95 | -0.09 |
Total Debt / EBITDA | - | - | -0.61 | -0.54 | -36.36 |
Net Debt / EBITDA | -8.67 | 0.69 | -0.53 | -0.42 | -26.07 |
Total Debt / (EBITDA - Capex) | - | - | -0.48 | -0.44 | -36.36 |
Net Debt / (EBITDA - Capex) | 0.97 | 0.19 | -0.41 | -0.35 | -26.07 |
Growth Over Prior Year | |||||
Total Revenues, 1 Yr. Growth % | - | 2.81 | -12.89 | -38.82 | -32.8 |
Gross Profit, 1 Yr. Growth % | - | -97.98 | -25.8 | -38.3 | -28.82 |
EBITDA, 1 Yr. Growth % | - | -461.74 | 320.32 | -28.21 | -98.32 |
EBITA, 1 Yr. Growth % | - | 4.24K | 227.57 | -26.35 | -86.87 |
EBIT, 1 Yr. Growth % | - | 239.76 | 211.03 | -26.01 | -85 |
Earnings From Cont. Operations, 1 Yr. Growth % | - | 156.17 | 167.46 | -28.14 | -69.44 |
Net Income, 1 Yr. Growth % | - | 154.71 | 169.4 | -28.12 | -69.09 |
Normalized Net Income, 1 Yr. Growth % | - | 157.01 | 177.73 | -23.21 | -69.66 |
Diluted EPS Before Extra, 1 Yr. Growth % | - | - | 150.92 | -28.12 | -69.09 |
Accounts Receivable, 1 Yr. Growth % | - | -8.98 | -4.89 | -48.13 | -41.69 |
Inventory, 1 Yr. Growth % | - | 20.58 | -48.63 | -43.08 | 15.78 |
Net Property, Plant and Equip., 1 Yr. Growth % | - | 19.09 | -22.5 | -63.32 | -57.4 |
Total Assets, 1 Yr. Growth % | - | 2.86 | -27.44 | -46.02 | -16.93 |
Tangible Book Value, 1 Yr. Growth % | - | -72.03 | -308.54 | 172.39 | 14 |
Common Equity, 1 Yr. Growth % | - | -31.43 | -76.56 | -386.11 | 42.42 |
Cash From Operations, 1 Yr. Growth % | - | -254.64 | -10.12 | 31.21 | -54.6 |
Capital Expenditures, 1 Yr. Growth % | - | -6.53 | -53.59 | -43.7 | - |
Levered Free Cash Flow, 1 Yr. Growth % | - | - | -106.76 | 895.52 | -69.5 |
Unlevered Free Cash Flow, 1 Yr. Growth % | - | - | -114.44 | 442.88 | -57.52 |
Compound Annual Growth Rate Over Two Years | |||||
Total Revenues, 2 Yr. CAGR % | - | - | -5.36 | -27 | -35.88 |
Gross Profit, 2 Yr. CAGR % | - | - | 368.98 | -32.34 | -33.73 |
EBITDA, 2 Yr. CAGR % | - | - | 290.13 | 73.71 | -89 |
EBITA, 2 Yr. CAGR % | - | - | 1.09K | 55.33 | -68.9 |
EBIT, 2 Yr. CAGR % | - | - | 225.18 | 51.7 | -66.69 |
Earnings From Cont. Operations, 2 Yr. CAGR % | - | - | 161.75 | 38.63 | -53.14 |
Net Income, 2 Yr. CAGR % | - | - | 161.95 | 39.15 | -52.86 |
Normalized Net Income, 2 Yr. CAGR % | - | - | 167.37 | 46.04 | -51.73 |
Diluted EPS Before Extra, 2 Yr. CAGR % | - | - | - | 34.3 | -52.86 |
Accounts Receivable, 2 Yr. CAGR % | - | - | -8.8 | -29.76 | -45 |
Inventory, 2 Yr. CAGR % | - | - | -21.29 | -45.93 | -18.82 |
Net Property, Plant and Equip., 2 Yr. CAGR % | - | - | -3.93 | -46.68 | -60.47 |
Total Assets, 2 Yr. CAGR % | - | - | -13.61 | -37.42 | -33.04 |
Tangible Book Value, 2 Yr. CAGR % | - | - | -23.63 | 138.33 | 76.22 |
Common Equity, 2 Yr. CAGR % | - | - | -59.91 | -18.11 | 101.86 |
Cash From Operations, 2 Yr. CAGR % | - | - | 17.9 | 8.6 | -22.82 |
Capital Expenditures, 2 Yr. CAGR % | - | - | -34.14 | -48.89 | - |
Levered Free Cash Flow, 2 Yr. CAGR % | - | - | - | -17.94 | 74.26 |
Unlevered Free Cash Flow, 2 Yr. CAGR % | - | - | - | -11.47 | 51.86 |
Compound Annual Growth Rate Over Three Years | |||||
Total Revenues, 3 Yr. CAGR % | - | - | - | -18.17 | -28.99 |
Gross Profit, 3 Yr. CAGR % | - | - | - | 138.52 | -31.18 |
EBITDA, 3 Yr. CAGR % | - | - | - | 121.9 | -62.95 |
EBITA, 3 Yr. CAGR % | - | - | - | 371.38 | -31.83 |
EBIT, 3 Yr. CAGR % | - | - | - | 98.52 | -29.86 |
Earnings From Cont. Operations, 3 Yr. CAGR % | - | - | - | 70.12 | -16.26 |
Net Income, 3 Yr. CAGR % | - | - | - | 70.22 | -15.72 |
Normalized Net Income, 3 Yr. CAGR % | - | - | - | 76.4 | -13.5 |
Diluted EPS Before Extra, 3 Yr. CAGR % | - | - | - | - | -17.7 |
Accounts Receivable, 3 Yr. CAGR % | - | - | - | -24.44 | -33.98 |
Inventory, 3 Yr. CAGR % | - | - | - | -29.35 | -30.31 |
Net Property, Plant and Equip., 3 Yr. CAGR % | - | - | - | -30.3 | -50.52 |
Total Assets, 3 Yr. CAGR % | - | - | - | -26.14 | -31.22 |
Tangible Book Value, 3 Yr. CAGR % | - | - | - | 16.69 | 86.39 |
Common Equity, 3 Yr. CAGR % | - | - | - | -22.82 | -1.52 |
Cash From Operations, 3 Yr. CAGR % | - | - | - | 22.18 | -18.8 |
Capital Expenditures, 3 Yr. CAGR % | - | - | - | -37.49 | - |
Levered Free Cash Flow, 3 Yr. CAGR % | - | - | - | - | -41 |
Unlevered Free Cash Flow, 3 Yr. CAGR % | - | - | - | - | -30.69 |
- Stock Market
- Stocks
- PINK Stock
- Financials Pilulka Lékárny
- Financial Ratios
Select your edition
All financial news and data tailored to specific country editions
















